Cargando…
The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
Glaucomatous optic atrophy is the second most common cause of blindness worldwide, and lowering intraocular pressure (IOP) is the only proven method to slow or stop the progression of the disease. Approximately 40% of patients with elevated IOP will require more than one medication to obtain a modes...
Autor principal: | Radcliffe, Nathan M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270356/ https://www.ncbi.nlm.nih.gov/pubmed/25540579 http://dx.doi.org/10.2147/OPTH.S76053 |
Ejemplares similares
-
Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Bell, Nicholas P, et al.
Publicado: (2010) -
Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma
por: Hommer, Anton, et al.
Publicado: (2015) -
Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension
por: Ichhpujani, Parul, et al.
Publicado: (2010) -
Efficacy and Tolerability of Fixed-Combination Brinzolamide/Timolol in Latin American Patients with Open-Angle Glaucoma or Ocular Hypertension Previously on Brimonidine/Timolol Fixed Combination
por: Alezzandrini, Arturo, et al.
Publicado: (2014) -
Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate
por: Kelly Rigollet, Jaime Pablo, et al.
Publicado: (2011)